405 related articles for article (PubMed ID: 29026304)
1. Prevention of doxorubicin-induced cardiomyopathy using targeted MaFGF mediated by nanoparticles combined with ultrasound-targeted MB destruction.
Tian XQ; Ni XW; Xu HL; Zheng L; ZhuGe DL; Chen B; Lu CT; Yuan JJ; Zhao YZ
Int J Nanomedicine; 2017; 12():7103-7119. PubMed ID: 29026304
[TBL] [Abstract][Full Text] [Related]
2. Advanced Interfere Treatment of Diabetic Cardiomyopathy Rats by aFGF-Loaded Heparin-Modified Microbubbles and UTMD Technique.
Zhang M; Yu WZ; Shen XT; Xiang Q; Xu J; Yang JJ; Chen PP; Fan ZL; Xiao J; Zhao YZ; Lu CT
Cardiovasc Drugs Ther; 2016 Jun; 30(3):247-61. PubMed ID: 26947349
[TBL] [Abstract][Full Text] [Related]
3. Prevent diabetic cardiomyopathy in diabetic rats by combined therapy of aFGF-loaded nanoparticles and ultrasound-targeted microbubble destruction technique.
Zhao YZ; Zhang M; Wong HL; Tian XQ; Zheng L; Yu XC; Tian FR; Mao KL; Fan ZL; Chen PP; Li XK; Lu CT
J Control Release; 2016 Feb; 223():11-21. PubMed ID: 26712588
[TBL] [Abstract][Full Text] [Related]
4. Using basic fibroblast growth factor nanoliposome combined with ultrasound-introduced technology to early intervene the diabetic cardiomyopathy.
Zhao YZ; Zhang M; Tian XQ; Zheng L; Lu CT
Int J Nanomedicine; 2016; 11():675-86. PubMed ID: 26937188
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment with ultrasound-targeted microbubble destruction technique and NM-aFGF-loaded PEG-nanoliposomes protects against diabetic cardiomyopathy-induced oxidative stress by activating the AKT/GSK-3β1/Nrf-2 pathway.
Zhang M; Zhu NW; Ma WC; Chen MJ; Zheng L
Drug Deliv; 2020 Dec; 27(1):938-952. PubMed ID: 32611270
[TBL] [Abstract][Full Text] [Related]
6. Functional and pathological improvements of the hearts in diabetes model by the combined therapy of bFGF-loaded nanoparticles with ultrasound-targeted microbubble destruction.
Zhao YZ; Tian XQ; Zhang M; Cai L; Ru A; Shen XT; Jiang X; Jin RR; Zheng L; Hawkins K; Charkrabarti S; Li XK; Lin Q; Yu WZ; Ge S; Lu CT; Wong HL
J Control Release; 2014 Jul; 186():22-31. PubMed ID: 24815422
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic effect of combined use of FGF1-loaded nano-liposomes and ultrasound-targeted microbubble destruction technique on treating rats with experimental diabetic cardiomyopathy].
Zhang M; Zhao YZ; Ma WC; Xu JL; Wang JL; Chen MJ; Yu L; Chen YN
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 May; 45(5):427-433. PubMed ID: 28511329
[No Abstract] [Full Text] [Related]
8. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53.
Zhang C; Feng Y; Qu S; Wei X; Zhu H; Luo Q; Liu M; Chen G; Xiao X
Cardiovasc Res; 2011 Jun; 90(3):538-45. PubMed ID: 21278141
[TBL] [Abstract][Full Text] [Related]
9. Brain-derived neurotrophic factor attenuates doxorubicin-induced cardiac dysfunction through activating Akt signalling in rats.
Hang P; Zhao J; Sun L; Li M; Han Y; Du Z; Li Y
J Cell Mol Med; 2017 Apr; 21(4):685-696. PubMed ID: 28098423
[TBL] [Abstract][Full Text] [Related]
10. Heat shock protein 20 interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity.
Fan GC; Zhou X; Wang X; Song G; Qian J; Nicolaou P; Chen G; Ren X; Kranias EG
Circ Res; 2008 Nov; 103(11):1270-9. PubMed ID: 18948619
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-29b Regulates the Mitochondria-Dependent Apoptotic Pathway by Targeting Bax in Doxorubicin Cardiotoxicity.
Jing X; Yang J; Jiang L; Chen J; Wang H
Cell Physiol Biochem; 2018; 48(2):692-704. PubMed ID: 30025410
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic clues to the protective effect of chrysin against doxorubicin-induced cardiomyopathy: Plausible roles of p53, MAPK and AKT pathways.
Mantawy EM; Esmat A; El-Bakly WM; Salah ElDin RA; El-Demerdash E
Sci Rep; 2017 Jul; 7(1):4795. PubMed ID: 28684738
[TBL] [Abstract][Full Text] [Related]
13. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
Xiang P; Deng HY; Li K; Huang GY; Chen Y; Tu L; Ng PC; Pong NH; Zhao H; Zhang L; Sung RY
Cancer Chemother Pharmacol; 2009 Jan; 63(2):343-9. PubMed ID: 18379782
[TBL] [Abstract][Full Text] [Related]
14. Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy.
Chen X; Chen Y; Bi Y; Fu N; Shan C; Wang S; Aslam S; Wang PW; Xu J
Cardiovasc Drugs Ther; 2007 Oct; 21(5):367-74. PubMed ID: 17924179
[TBL] [Abstract][Full Text] [Related]
15. α-Linolenic acid attenuates doxorubicin-induced cardiotoxicity in rats through suppression of oxidative stress and apoptosis.
Yu X; Cui L; Zhang Z; Zhao Q; Li S
Acta Biochim Biophys Sin (Shanghai); 2013 Oct; 45(10):817-26. PubMed ID: 23896563
[TBL] [Abstract][Full Text] [Related]
16. aFGF Targeted Mediated by Novel Nanoparticles-Microbubble Complex Combined With Ultrasound-Targeted Microbubble Destruction attenuates Doxorubicin-Induced Heart Failure via Anti-Apoptosis and Promoting Cardiac Angiogenesis.
Zhou NQ; Fang ZX; Huang N; Zuo Y; Qiu Y; Guo LJ; Song P; Xu J; Wan GR; Tian XQ; Yin YL; Li P
Front Pharmacol; 2021; 12():607785. PubMed ID: 33986662
[TBL] [Abstract][Full Text] [Related]
17. Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy.
van Almen GC; Swinnen M; Carai P; Verhesen W; Cleutjens JP; D'hooge J; Verheyen FK; Pinto YM; Schroen B; Carmeliet P; Heymans S
J Mol Cell Cardiol; 2011 Sep; 51(3):318-28. PubMed ID: 21624372
[TBL] [Abstract][Full Text] [Related]
18. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
Mohamed HE; Asker ME; Ali SI; el-Fattah TM
J Pharm Pharmacol; 2004 Jun; 56(6):757-68. PubMed ID: 15231041
[TBL] [Abstract][Full Text] [Related]
19. Cardiac Fgf-16 Expression Supports Cardiomyocyte Survival and Increases Resistance to Doxorubicin Cytotoxicity.
Wang J; Xiang B; Dolinsky VW; Kardami E; Cattini PA
DNA Cell Biol; 2018 Nov; 37(11):866-877. PubMed ID: 30230915
[TBL] [Abstract][Full Text] [Related]
20. Astragaloside IV alleviates doxorubicin induced cardiomyopathy by inhibiting NADPH oxidase derived oxidative stress.
Lin J; Fang L; Li H; Li Z; Lyu L; Wang H; Xiao J
Eur J Pharmacol; 2019 Sep; 859():172490. PubMed ID: 31229536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
